FD-001
/ FenDi Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
January 06, 2025
A Phase 1 Study of FD-001 in Recurrent /Refractory (R/R)AML/NHL/MM/MDS
(clinicaltrials.gov)
- P1 | N=72 | Recruiting | Sponsor: Chengdu FenDi Pharmaceutical Co., Ltd. | Phase classification: P1/2 ➔ P1
Phase classification • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Myelodysplastic Syndrome • Non-Hodgkin’s Lymphoma • Oncology
December 12, 2024
A Phase 1 Study of FD-001 in Recurrent /Refractory (R/R)AML/NHL/MM/MDS
(clinicaltrials.gov)
- P1/2 | N=72 | Recruiting | Sponsor: Chengdu FenDi Pharmaceutical Co., Ltd.
New P1/2 trial • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Myelodysplastic Syndrome • Non-Hodgkin’s Lymphoma • Oncology
1 to 2
Of
2
Go to page
1